• Complicated intra-abdominal infections.

Contraindicated in:

• Hypersensitivity to eravacycline or other tetracycline antibiotics
• OB: Pregnancy (may lead to permanent staining of teeth and inhibition of bone growth in fetus if used during 2nd or 3rd trimester)
• Lactation: Lactation
• Pedi: Children <8 yr (may lead to permanent staining of teeth and ↓ growth).

Use Cautiously in:

• Severe hepatic impairment
• Pedi: Safety and effectiveness not established in children.

CV: hypotension.

Derm: photosensitivity.

GI: CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), diarrhea, nausea, vomiting.

GU: ↓fertility (males).

Local: infusion site reaction.

Neuro: intracranial hypertension.
Misc: (INCLUDING ANAPHYLAXIS)HYPERSENSITIVITY REACTIONS .

Drug-Drug:

• Strong CYP3A inducers may ↓ levels; ↑ eravacycline dose.
• May ↑ effect of warfarin.

• Lyophilized powder for injection: 50 mg/vial; 100 mg/vial;

• IV (Adults): 1 mg/kg every 12 hr for 4–14 days. Concurrent use of strong CYP3A inducer: 1.5 mg/kg every 12 hr for 4–14 days.

Xerava

• Inhibits bacterial protein synthesis by binding to the 30S bacterial ribosome.

• Bacteriostatic against gram-positive bacteria. Bactericidal against certain strains of Escherichia coli and Klebsiella pneumoniae.

Spectrum:

• Active against some gram-positive pathogens:
  • Enterococcus faecalis,
  • Enterococcus faecium,
  • Staphylococcus aureus,
  • Streptococcus anginosus.
• Active against some gram-negative pathogens:
  • Citrobacter freundii,
  • Enterobacter cloacae,
  • Escherichia coli,
  • Klebsiella oxytoca,
  • Klebsiella pneumoniae.
• Active against some anaerobic pathogens:
  • Bacteroides spp.,
  • Clostridium perfringens,
  • Parabacteroides distasonis.

Therapeutic Classification: anti-infectives

Pharmacologic Classification: tetracyclines

Absorption: IV administration results in complete bioavailability.

Distribution: Extensively distributed to tissues.

Protein Binding: 79–90% (↑ as plasma concentrations ↑).

Metabolism/Excretion: Primarily metabolized by the liver by CYP3A enzymes. 47% excreted in feces (17% as unchanged drug), 34% in urine (20% as unchanged drug).

Half-life: 20 hr.

(plasma concentrations)

• Explain purpose of eravacycline to patient. Emphasize the importance of completing full course of therapy and not skipping doses.
• Instruct patient to notify health care professional immediately if rash, diarrhea, abdominal cramping, fever, or bloody stools occur and not to treat with antidiarrheals without consulting health care professionals. Diarrhea may occur as late as 2 mo after therapy.
• Caution patient to use sunscreen and protective clothing to prevent photosensitivity reactions.
• Advise patient to report the signs of superinfection (black, furry overgrowth on the tongue, vaginal itching or discharge, loose or foul-smelling stools).
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• May cause tooth discoloration and inhibition of bone growth if administered during 2nd and 3rd trimesters. Advise females of reproductive potential to use a nonhormonal method of contraception while taking tetracyclines and until next menstrual period and to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during and for 4 days after last dose of eravacycline. May cause infertility in male patients.

ER-a-va-SYE-kleen